Petvivo Holdings, Inc. (PETVW) — SEC Filings
Petvivo Holdings, Inc. (PETVW) — 50 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 34 8-K, 6 SC 13G/A, 5 10-Q.
View Petvivo Holdings, Inc. on SEC EDGAR
Overview
Petvivo Holdings, Inc. (PETVW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: PetVivo Holdings, Inc. (PETVW) reported a significant increase in revenue for the six months ended September 30, 2025, reaching $600,784, up 85.1% from $324,470 in the same period of 2024. Gross profit also rose to $406,784 from $290,314 year-over-year. Despite revenue growth, the company's net loss
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 5 bearish, 44 neutral, 1 mixed. The dominant filing sentiment for Petvivo Holdings, Inc. is neutral.
Filing Type Overview
Petvivo Holdings, Inc. (PETVW) has filed 5 10-Q, 34 8-K, 1 10-K, 6 SC 13G/A, 2 SC 13G, 1 10-K/A, 1 SC 13D/A with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PETVW's 41 recent filings, 6 were flagged as high-risk, 29 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $600,784 |
| Net Income | $(5,472,449) |
| Cash Position | $767,914 |
| Total Assets | $5,258,269 |
Key Executives
- Dr. Robert L. Smith
- Dr. Michael J. Smith
- Stanley C. Cruden
- Dr. Steven L. St. Clair
- Mr. David L. Johnson
- Mr. Robert L. Johnson
- Mr. David A. L. Williams
- Mr. Jeffrey S. N. Kim
- John K. Nielsen
- Brent L. R. Jones
- Dr. Brent R. Burns
- Dr. Robert J. Valeri
Industry Context
PetVivo Holdings operates in the animal health sector, focusing on innovative medical devices and therapeutics for pets. The industry is characterized by increasing pet ownership and a willingness among owners to spend on advanced veterinary care. Key trends include the development of regenerative medicine and novel drug delivery systems. Competition comes from established veterinary pharmaceutical companies and other specialized device manufacturers.
Top Tags
material-agreement (8) · financials (8) · equity-sale (6) · corporate-governance (5) · executive-compensation (5) · filing (5) · material-definitive-agreement (5) · Biomaterials (3) · board-changes (3) · regulatory-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for six months ended Sep 30, 2025 | $600,784 | Increased 85.1% from $324,470 in prior year |
| Net Loss Available to Common Stockholders for six months ended Sep 30, 2025 | $(5,472,449) | Widened from $(4,222,556) in prior year |
| Cash at September 30, 2025 | $767,914 | Increased from $227,689 at March 31, 2025 |
| Total Assets at September 30, 2025 | $5,258,269 | Decreased from $9,339,195 at March 31, 2025 |
| Interest Expense for six months ended Sep 30, 2025 | $1,064,250 | Significantly increased from $(5,083) in prior year |
| Convertible debentures and accrued interest converted to common stock | $2,018,154 | Non-cash financing activity, indicating significant debt-to-equity conversion |
| Common Stock shares outstanding at September 30, 2025 | 32,954,679 | Increased from 24,181,537 at March 31, 2025, indicating dilution |
| Commission File Number | 001-40715 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 99-0363559 | Company's tax identification number. |
| Revenue for Q1 2025 | $297,500 | Increased 140.4% from $123,751 in Q1 2024 |
| Net Loss for Q1 2025 | $2,311,037 | Widened from $2,047,063 in Q1 2024 |
| Cash at June 30, 2025 | $3,303,844 | Significant increase from $227,689 at March 31, 2025 |
| Proceeds from preferred stock subscription receivable | $4,400,000 | Key driver of cash increase in Q1 2025 |
| Total Assets at June 30, 2025 | $6,890,496 | Decreased from $9,339,195 at March 31, 2025 |
| Total Liabilities at June 30, 2025 | $3,159,519 | Decreased from $5,119,947 at March 31, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Petvivo Holdings, Inc. (PETVW)?
Petvivo Holdings, Inc. has 50 recent SEC filings from Mar 2024 to Nov 2025, including 34 8-K, 6 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PETVW filings?
Across 50 filings, the sentiment breakdown is: 5 bearish, 44 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Petvivo Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Petvivo Holdings, Inc. (PETVW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Petvivo Holdings, Inc.?
Key financial highlights from Petvivo Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PETVW?
The investment thesis for PETVW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Petvivo Holdings, Inc.?
Key executives identified across Petvivo Holdings, Inc.'s filings include Dr. Robert L. Smith, Dr. Michael J. Smith, Stanley C. Cruden, Dr. Steven L. St. Clair, Mr. David L. Johnson and 7 others.
What are the main risk factors for Petvivo Holdings, Inc. stock?
Of PETVW's 41 assessed filings, 6 were flagged high-risk, 29 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Petvivo Holdings, Inc.?
Forward guidance and predictions for Petvivo Holdings, Inc. are extracted from SEC filings as they are enriched.